Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:35:45.769Z.
Calculation as of: 2026-10-06T13:35:45.769Z.
Quote observation: 2026-10-06T13:30:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a667a199b47e7e336467208d2f6772290b800d1a0ab6507ee3a182ebbb9f075
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$117.48M
PS Ratio
14685.24
TTM Avg
12612.95
3Y Avg
8591.50
5Y Avg
6492.60
Market Cap
$118.42M
PS Ratio
11.80
TTM Avg
17.12
3Y Avg
13.55
5Y Avg
29.14
Market Cap
$115.66M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$120.80M
PS Ratio
72.33
TTM Avg
60.78
3Y Avg
38.49
5Y Avg
33.17
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $117.87M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $117.48M | 14685.24 | 12612.95 | 8591.50 | 6492.60 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.42M | 11.80 | 17.12 | 13.55 | 29.14 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | 3.15 | 11.54 | 10.77 | 81.00 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.80M | 72.33 | 60.78 | 38.49 | 33.17 |
| Coya Therapeutics, Inc. (COYA)vs › | $114.35M | 14.26 | 42.02 | 39.60 | 39.60 |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.20M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | 5.34 | 34.83 | 63.67 | 63.67 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.02M | N/A | 2.32 | 2.32 | 2.32 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
